We track 50 documented policy changes from Independence Blue Cross across DE, MA, NJ, NY, PA and 1 more states. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original Independence Blue Cross notice. Use the related links below to narrow results by specialty or state, or create a free alert to get new Independence Blue Cross updates by email (daily or weekly, your choice, on every plan).
Independence Blue Cross MA05.023e adds new billing requirements effective 11/16/2026 that restrict unbundling of wheelchair cushion and seating codes. Codes E1033 and E1034 cannot be billed together with specific positioning accessory codes (E0953, E0955, E0956, E0957, E0960) and cannot be used for mounting hardware. Billing teams must update claim submission logic to enforce these code-combination restrictions.
Effective 11/30/2026, Independence Blue Cross Medicare Advantage is updating medical policy MA12.010e to change remote patient monitoring (RPM and RTM) coverage from a blanket covered status to medically necessary with specific criteria. Coverage is now limited to patients with heart failure, hypertension, or diabetes mellitus, with 16 CPT/HCPCS codes now eligible only when specific diagnoses and clinical criteria are met. Billing teams must update authorization logic, documentation requirements, and claim submission workflows to reflect the new diagnosis-based eligibility rules.
Independence Blue Cross Medicare Advantage is revising coverage for acellular dermal matrices (ADM) in reconstructive breast surgery effective 12/08/2026. Eight HCPCS codes are being removed from this policy and reclassified as experimental/investigational or moved to the Bioengineered Skin Substitutes policy (MA11.015). Additionally, Q4130 (Strattice) and Q4433 (361 hct/p skin substitute) are changing from medically necessary to experimental/investigational status. Billing teams must stop using these codes for reconstructive breast surgery claims and verify coverage under the new policy before claim submission.
Independence Blue Cross Medicare Advantage is restricting trigger point injection coverage effective 01/01/2027 by limiting frequency to 3-4 sessions per 12 months, eliminating corticosteroid and other injectates (anesthetic-only now covered), removing image guidance coverage, and restricting covered diagnoses to myofascial pain (M79.12, M79.18 only). Multiple HCPCS codes for injectates and CPT codes for imaging guidance are now classified as not medically necessary.
Independence Blue Cross significantly restricts trigger point injection (TPI) coverage effective 01/01/2027: frequency reduced to 3 injections per 12 months (max 4 with documentation), coverage limited to anesthetic-only injections for myofascial pain diagnoses M79.12 and M79.18, image guidance (ultrasound, fluoroscopy, MRI) and corticosteroid injectates are no longer covered, and 13 HCPCS codes and 3 CPT codes are reclassified as not medically necessary.
Independence Blue Cross is revising its Hematopoietic Stem Cell Transplantation policy effective 02/01/2027. Key changes include reclassifying tandem autologous transplantation for Hodgkin Lymphoma as experimental, removing Durie-Salmon staging criteria from Multiple Myeloma coverage, expanding Omisirge eligibility, removing G-CSF products from this policy (they move to primary drug policies), and removing five G-CSF-related HCPCS codes from coverage under this policy.
Effective 12/02/2026, Independence Blue Cross establishes a new medical policy covering remote physiologic monitoring (RPM) and remote therapeutic monitoring (RTM) for commercial members with specific chronic and acute conditions (CHF, hypertension, diabetes) when medically necessary criteria are met. The policy defines covered CPT and HCPCS codes, requires FDA-approved devices, patient consent documentation, provider supervision, and limits initial coverage to specific monitoring periods with documented clinical justification for extensions beyond 60 days.
Independence Blue Cross expanded coverage of teplizumab-mzwv (Tzield) effective 12/07/2026 to include pediatric individuals ages 1 to <8 years with stage 2 type 1 diabetes. Simultaneously, the policy clarified that use in ages 8-17 with stage 3 T1D remains experimental/investigational and not covered. Six ICD-10 diagnosis codes (R73.01, R73.02, R73.03, R73.09, R76.0, Z83.3) were removed from the policy.
Independence Blue Cross expanded coverage for Teplizumab-mzwv (Tzield) to include pediatric patients aged 1 to <8 years with stage 2 type 1 diabetes, while maintaining non-coverage for patients aged 8-17 with stage 3 T1D (classified as experimental/investigational). Six ICD-10 diagnosis codes were removed from the policy. Billing teams must update systems to reflect the new pediatric age coverage expansion effective December 7, 2026.
Independence Blue Cross has updated policy 00.01.52ad to clarify that venipuncture (CPT codes 36400, 36405, 36406, 36410, 36415, 36416, 36591, 36592) is not eligible for separate reimbursement to outpatient facilities when performed incidental to laboratory services. These codes are now added to Attachment D, meaning they cannot be billed separately when reported with other services on the same date by the same provider.
Independence Blue Cross Medicare Advantage added face-to-face encounter and written order prior authorization requirements for seven manual wheelchair HCPCS codes (K0002, K0003, K0004, K0005, K0006, K0007, E1161) effective 10/28/2026. The practice must obtain prior authorization before delivering these wheelchairs to members.
Independence Blue Cross Medicare Advantage added Face-to-Face Encounter and Written Order Prior to Delivery and/or Prior Authorization requirements to eight wheelchair and wheelchair accessory HCPCS codes (E1161, K0002, K0003, K0004, K0005, K0006, K0007, K0831) effective 10/28/2026. The practice must obtain prior authorization before delivering these items to IBC MA members.
Independence Blue Cross Medicare Advantage added face-to-face encounter and written order prior authorization requirements for home oxygen equipment codes K0738 (effective 10/28/2026) and E0424, E0431, E0433, E0434, E0439, E1390, E1391, E1392 (effective 04/13/2026, which has already passed). The practice must now obtain prior authorization before delivering these oxygen devices to Medicare Advantage members.
Independence Blue Cross added face-to-face encounter and written order prior authorization requirements to eight wheelchair HCPCS codes (E1161, K0002, K0003, K0004, K0005, K0006, K0007, K0831) effective 10/28/2026, aligning with Medicare Final Rule. The practice must obtain prior authorization before these wheelchairs are delivered or prior to authorization issuance.
Independence Blue Cross added face-to-face encounter and written order prior authorization requirements to home oxygen therapy HCPCS codes. Code K0738 requires prior auth effective 10/28/2026 (already in effect as of analysis date). Codes E0424, E0431, E0433, E0434, E0439, E1390, E1391, E1392 had similar language added effective 04/13/2026 (past deadline). The billing team must confirm prior auth processes are in place for these codes and that claims are not submitted without authorization.
Independence Blue Cross Medicare Advantage is adding face-to-face encounter requirements for three HCPCS codes (L0456, L0457, L0486) for spinal orthoses, effective 10/28/2026. Providers must document an in-person evaluation within 6 months prior to the written order for each new orthosis ordered, or claims will be denied.
Independence Blue Cross Medicare Advantage policy MA08.142f adds new contraindication restrictions for efgartigimod alfa-fcab (Vyvgart) effective 10/26/2026, prohibiting concurrent use with FcRn blockers, complement inhibitors, immune globulin, and requiring neurologist involvement. The policy also removes the previous AChR antibody-positive requirement for gMG coverage. Billing teams must update prior authorization rules and clinical criteria checks before the October effective date.
Independence Blue Cross updated policy 08.00.46f to add coverage for a new subcutaneous formulation of isatuximab-irfc (Sarclisa Escena), approved by FDA on July 9, 2026, for multiple myeloma treatment. The policy also expanded coverage criteria for the intravenous formulation (Sarclisa) to include additional primary therapy regimens and added coverage for plasma cell-related conditions (POEMS, MIDD, MGRS). New HCPCS and ICD-10 diagnosis codes have been added to support billing for both formulations.
Independence Blue Cross updated policy 08.02.19b for mirikizumab-mrkz (Omvoh) IV effective 10/19/2026. Coverage criteria were revised to align with updated ACG guidelines, removing conventional therapy requirements. Billing teams must now append modifier JA to indicate intravenous administration, and must use the reintroduced ICD-10 diagnosis codes for ulcerative colitis and Crohn's disease claims.
Independence Blue Cross updated MA00.002t to clarify coverage criteria and benefits for continuous glucose monitors (CGM) and home blood glucose monitor supplies, effective 10/05/2026. New HCPCS code E2103 was added to reimbursement edits Column I, and 19 additional HCPCS codes (E0607, E2100, E2101, A4233-A4236, A4244-A4247, A4250, A4253, A4255-A4259) were added to Column II. Policy language was revised for clarity regarding short-term and long-term CGM systems, preferred brands, and medical necessity criteria aligned with current Medicare guidelines.
Independence Blue Cross Medicare Advantage updated laboratory services policy MA00.030am, effective 10/01/2026, adding 39 new CPT codes (0660U-0698U) to the capitated laboratory services list, terminating CPT code 0585U, and revising narratives for codes 0247U, 0575U, and 0591U. HMO and HMO-POS members must obtain lab services at their PCP's designated capitated laboratory site, with limited exceptions for specialist offices and outpatient hospital laboratories.
Independence Blue Cross Medicare Advantage added ICD-10 code F64.A (Gender identity disorder, in remission) as NOT medically necessary for leuprolide acetate products (J1950, J9217, J1951, J1952), effective 10/01/2026. This exclusion means claims for leuprolide with this diagnosis code will be denied. The policy also clarifies preferred vs. nonpreferred leuprolide products, with preferred products (Eligard, Lupron Depot 7.5 mg) designated for prostate cancer and salivary gland tumors.
Independence Blue Cross updated ICD-10 diagnosis codes for cardiac rehabilitation coverage effective 10/01/2026. Six cardiomyopathy codes were replaced with more specific granular codes (I42.0 and I42.8 terminated; I42.00, I42.01, I42.09, I42.81, and I42.89 added). Billing teams must update systems to use only the new codes to avoid claim denials.
Independence Blue Cross updated ICD-10 diagnosis codes for Medicare Advantage AECG/MCOT monitoring policy effective 10/01/2026. Three broad cardiomyopathy and arrhythmia codes (I42.0, I42.8, I49.8) were terminated and replaced with nine more specific codes that provide granular differentiation (e.g., familial-genetic dilated cardiomyopathy, Brugada syndrome, CPVT). Billing teams must update systems to use only the new codes to avoid claim denials.
Independence Blue Cross Medicare Advantage has added four new CPT codes (1057T, 1058T, 1059T, 1060T, 1061T) to policy MA11.019n effective 10/01/2026, classified as Experimental/Investigational for vagus nerve stimulation. These codes are NOT covered and should not be billed to Medicare Advantage plans. The policy maintains coverage only for medically refractory seizures under specific criteria.
Independence Blue Cross updated MA05.060h to add new HCPCS codes for external infusion pumps and fluorouracil injections, effective 10/01/2026. Four codes were added (A4228, E0788, J9191, J9192) and one code was deleted (J9190). Additionally, eight HCPCS equipment codes now require Face-to-Face Encounter and Written Order Prior to Delivery documentation per Medicare Final Rule.
Independence Blue Cross MA05.010m updated HCPCS codes for ankle-foot orthoses effective 10/01/2026: code L1971 (customized prefabricated AFO) was revised, new code L1972 (off-the-shelf AFO) was added to medically necessary section, and ICD-10 codes for plantar fasciitis and plantar fascial fibromatosis were expanded with laterality specificity (M67.A01, M67.A02, M67.A09, M72.20, M72.21, M72.22), replacing the non-specific M72.2 code.
Independence Blue Cross published an update to its Medicare Advantage medical policy MA11.015ah on bioengineered skin substitutes on 2026-10-01, stating it became effective 10/01/2026, which is already in the past as of today. The lower extremity wound criteria, documentation and billing rules now directly follow CMS criteria, a Biobrane glove was added for second- and third-degree burns, and a long list of HCPCS codes was added as eligible while several CPT codes were marked experimental. Confirm with Independence Blue Cross that this is still the current version before relying on it.
Independence Blue Cross Medicare Advantage is revising bundling policies effective 10/01/2026. CPT code 99459 (pelvic exam during E/M) is now classified as not eligible for separate reimbursement and has been added to Attachment B. HCPCS codes G9037 and G9038 have been terminated and removed from Attachment C. Billing teams must stop billing these codes separately and ensure providers understand they cannot bill members for these services.
Independence Blue Cross Medicare Advantage is restricting reimbursement for Modifier 59 claims unless they are time-based services; non-time-based services must now use the more specific modifiers XE, XP, XS, or XU to indicate distinct services performed on the same date. This represents a significant tightening of modifier usage rules and requires billing teams to audit and correct claim submission practices.
Independence Blue Cross has published a new Medicare Advantage policy (MA11.121) effective October 1, 2026, that classifies intraosseous basivertebral nerve ablation (Intracept system) as experimental/investigational and NOT COVERED for all indications including vertebrogenic back pain. This replaces previous guidance in the Experimental/Investigational Services policy (MA00.005). Billing teams must deny all claims for CPT codes 64628 and 64629 under Medicare Advantage plans.
Independence Blue Cross updated policy 00.03.07au effective 10/01/2026 to add 39 new laboratory CPT codes (0660U-0698U) to the capitated laboratory program for HMO/HMO-POS members, terminate CPT code 0585U, and revise narratives for codes 0247U, 0575U, and 0591U. These codes must now be billed to the member's PCP-designated capitated laboratory site, not to non-capitated facilities, or claims will be denied.
Independence Blue Cross updated ICD-10 diagnosis codes effective 10/01/2026 for catheter ablation of cardiac arrhythmias (Policy 11.02.06s). The code I49.8 (Other specified cardiac arrhythmias) was terminated and replaced with three more specific codes: I49.81 (Brugada syndrome), I49.82 (Ventricular bigeminy), and I49.89 (Other specified cardiac arrhythmias not elsewhere classified). Billing teams must update coding systems to use the new codes for claims on or after the effective date.
Independence Blue Cross updated ICD-10 diagnosis codes for AECG/MCOT monitoring policy effective 10/01/2026. Nine codes were terminated and replaced with more specific codes that better capture dilated cardiomyopathy subtypes, arrhythmogenic cardiomyopathy, and specific arrhythmia diagnoses including CPVT, Brugada syndrome, and ventricular bigeminy. Billing teams must update claim submission systems to use only the new codes to avoid claim denials.
Independence Blue Cross updated ICD-10 diagnosis codes effective 10/01/2026 for Policy 05.00.77g (Implantable Cardioverter Defibrillators). Three codes were terminated (I42.0, I42.8, I49.8) and nine new codes were added with greater specificity, including new codes for Brugada syndrome (I49.81), catecholaminergic polymorphic ventricular tachycardia (I47.22), ventricular bigeminy (I49.82), and arrhythmogenic cardiomyopathy (I42.81). The policy itself was not fully reviewed; this is a routine annual ICD-10 code update.
Independence Blue Cross updated policy 05.00.39x effective 10/01/2026 to add new HCPCS code L1972 (prefabricated, off-the-shelf ankle-foot orthosis) to the medically necessary/covered section and revised the definition of existing code L1971 (customized prefabricated ankle-foot orthosis). Billing teams must implement these code changes in their systems and ensure claims are submitted using the correct code based on whether the orthosis is off-the-shelf or customized.
Independence Blue Cross updated its bioengineered skin substitute policy (11.08.20at), effective 10/01/2026. Eight HCPCS codes (A2046, A2047, A2048, A2049, A2050, Q4207, Q4223, Q4243) are now classified as always experimental/investigational across all indications, and six additional codes were revised on the policy attachment. The policy tightened medical necessity criteria for chronic lower extremity wounds, requiring specific documentation of failed conservative treatment and adequate circulation/oxygenation.
Independence Blue Cross revised its Medicare Advantage medical policy MA11.015ah on bioengineered skin substitutes, effective 10/01/2026. The lower extremity wound criteria, documentation and billing rules now directly follow CMS criteria, a Biobrane glove was added for second- and third-degree burns, and a long list of HCPCS codes was added as eligible while several CPT codes were marked experimental. Because the effective date has already passed as of today, confirm with Independence Blue Cross that this is still the current version before relying on it.
Independence Blue Cross revised coverage criteria for bioengineered skin substitutes effective 10/01/2026, including changes to the list of covered products, medically necessary criteria for chronic lower extremity wounds, and experimental/investigational classifications. Eight HCPCS codes (A2046, A2047, A2048, A2049, A2050, Q4207, Q4223, Q4243) were added as always experimental/investigational, and six codes (A2040, A2041, A2042, A2043, A2045, Q4298, Q4299) were revised. Four G-codes (G0681, G0682, G0683, G0684) had effective dates moved to 01/01/2026.
Independence Blue Cross updated its bioengineered skin substitutes policy effective 10/01/2026, revising the list of covered products for lower extremity ulcers, burns, and epidermolysis bullosa. Eight HCPCS codes (A2046, A2047, A2048, A2049, A2050, Q4207, Q4223, Q4243) moved from medically necessary to experimental/investigational status, while six codes (A2040, A2041, A2042, A2043, A2045, Q4298, Q4299) were revised on the policy attachment. Four G-codes (G0681-G0684) had their effective dates moved to 01/01/2026. Medical necessity criteria for chronic lower extremity wounds were clarified, and experimental/investigational uses (acute wounds, post-Mohs, post-surgical) were explicitly defined.
Independence Blue Cross Medicare Advantage is restricting reimbursement for Modifier 59 claims effective 10/01/2026. Non-time-based services with Modifier 59 will no longer be reimbursed; providers must use the more specific modifiers XE, XP, XS, or XU instead. Time-based services may still use Modifier 59 only when the specific modifiers do not better describe the service. Additionally, modifiers cannot be appended to E/M codes, and multiple modifiers cannot be applied to a single procedure code.
Independence Blue Cross has updated its modifier policy (03.00.08g) effective 10/01/2026 to restrict reimbursement of Modifier 59 claims. Non-time-based services reported with Modifier 59 are now denied; providers must use the more specific modifiers XE, XP, XS, or XU instead. Time-based services with Modifier 59 remain eligible only when more specific modifiers do not better describe the service.
Policy 08.00.82r establishes coverage and medical necessity criteria for Ustekinumab (Stelara) administered via intravenous infusion. This is a new or significantly revised policy affecting pharmacy coverage, reimbursement positions, and required clinical documentation for this biologic immunosuppressant. The billing team must implement new prior authorization requirements and medical necessity validation protocols immediately.
Independence Blue Cross Medicare Advantage updated policy MA00.047u effective 09/19/2026 to reflect Carelon Medical Benefits Management's revised Clinical Appropriateness Guidelines for Musculoskeletal-Spine Surgery and Sacro-iliac Joint Fusion. Utilization management for select spinal surgical, joint surgical, and interventional pain management procedures will continue to be based on Medicare guidelines (LCD/NCD) or Carelon's Clinical Appropriateness Guidelines if no Medicare guideline exists. All musculoskeletal surgical procedures listed require precertification/preapproval, with some services also requiring level of care review.
Independence Blue Cross has delegated utilization management for percutaneous coronary intervention, coronary angiography, and arterial ultrasound services to Carelon Medical Benefits Management, effective 09/19/2026. The policy establishes a three-tier medical necessity determination process: first using Medicare NCDs/LCDs, then Carelon's Clinical Appropriateness Guidelines if no Medicare guidance exists, and denying services not addressed in either framework. Emergency procedures are excluded from utilization management.
Independence Blue Cross updated Policy 00.01.66u to reflect Carelon Medical Benefits Management's revised Clinical Appropriateness Guidelines for Musculoskeletal-Spine Surgery and Sacroiliac Joint Fusion, effective 09/19/2026. All spinal surgical procedures, joint surgical procedures, and interventional pain management procedures now require precertification based on Carelon's guidelines, with level of care review responsibilities delegated to Carelon for select services marked with an asterisk in the policy attachments.
Independence Blue Cross has delegated utilization management for percutaneous coronary intervention, coronary angiography, and arterial ultrasound to Carelon Medical Benefits Management, effective 09/19/2026. All determinations of medical necessity for these procedures will now follow Carelon's Clinical Appropriateness Guidelines instead of Independence's own criteria. Emergency procedures are exempt from utilization management requirements.
Independence Blue Cross has delegated utilization management for high-technology radiology services (CT, MRI, PET, echocardiography, and others) to Carelon Medical Benefits Management effective 09/19/2026. Prior authorization determinations will follow Medicare guidelines (NCD/LCD) first, then Carelon's Advanced Imaging Clinical Appropriateness Guidelines if Medicare guidelines don't exist. Emergency room, inpatient, and observation unit services are excluded from this delegation.
Independence Blue Cross has delegated utilization management for high-technology radiology services (CT, CTA, MRI, PET, ultrasound, nuclear medicine) to Carelon Medical Benefits Management, effective 09/19/2026. Carelon will now determine medical necessity using their Advanced Imaging Clinical Appropriateness Guidelines and conduct site-of-care reviews for select outpatient services. The policy does not apply to emergency room, inpatient, or observation unit stays.
Independence Blue Cross Commercial policy 08.00.85u on tocilizumab IV products and biosimilars was updated to take effect 09/14/2026, which is already in effect as of today. It revises the CAR T-cell toxicity criteria, adds criteria for Kaposi sarcoma-associated inflammatory cytokine syndrome, extends the hospitalized COVID-19 criteria to children age 2 and older, revises the juvenile idiopathic arthritis and rheumatoid arthritis criteria, and adds a long list of ICD-10 diagnosis codes as medically necessary. Because the source is a notice from the payer's own bulletin, confirm the current version with Independence Blue Cross before relying on it.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.